Company Analysis
Sign in

Aclaris Therapeutics, Inc. (ACRS)

Nasdaq: ACRS · Pharmaceutical Preparations · Wayne, PA · filing with the SEC since 2012
Full chart Alerts Compare
Grade3.8
◀ Past 4.7● Present 3.9▶ Future 3.2
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

20 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Aclaris Therapeutics, Inc.’s names, not what it holds today.

Patents granted
20
20 utility, 1976 to Dec 31, 2025
Granted in 2025
5
Against none in 2024 and 4 in 2023
Applications published
38
1 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'15'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals8
Organic fine chemistry2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
ACLARIS THERAPEUTICS, INC. its own name
named as the applicant on its applications, in US
0 granted
36 published
Aclaris Therapeutics, Inc. its own name
US, as the owner printed on each patent
20 granted
2 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 2, 202512,403,141Deuterated MK2 pathway inhibitors and methods of using the samePharmaceuticalsAclaris Therapeutics, Inc.
Aug 12, 202512,384,757Methods of synthesizing substituted pyridinone-pyridinyl compoundsOrganic fine chemistryAclaris Therapeutics, Inc.
Jul 29, 202512,370,195Oral compositions of MK2 pathway inhibitor for treatment of immune conditionsPharmaceuticalsAclaris Therapeutics, Inc.
May 13, 202512,297,203Pyrrolopyrimidine ITK inhibitorsPharmaceuticalsAclaris Therapeutics, Inc.
Apr 22, 202512,281,111Substituted pyrrolopyridine JAK inhibitors and methods of making and using the samePharmaceuticalsAclaris Therapeutics, Inc.
Dec 19, 202311,844,801Oral compositions of MK2 pathway inhibitor for treatment of immune conditionsPharmaceuticalsAclaris Therapeutics, Inc.
Nov 21, 202311,820,775Pyrrolopyrimidine ITK inhibitorsPharmaceuticalsAclaris Therapeutics, Inc.
Sep 26, 202311,767,309Methods of synthesizing substituted pyridinone-pyridinyl compoundsOrganic fine chemistryAclaris Therapeutics, Inc.
Aug 29, 202311,739,086Substituted pyrrolopyridine JAK inhibitors and methods of making and using the samePharmaceuticalsAclaris Therapeutics, Inc.
Apr 20, 202110,981,906Substituted pyrrolopyridine JAK inhibitors and methods of making and using the samePharmaceuticalsAclaris Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0387393ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONSPharmaceuticalsAclaris Therapeutics, Inc.
Jun 20, 20242024/0197732ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONSPharmaceuticalsACLARIS THERAPEUTICS, INC. · patent 12,370,195 granted from it
May 2, 20242024/0139170TOPICAL FORMULATIONS OF A JAK 1/3 INHIBITOR AND METHODS OF USE THEREOF FOR TREATMENT OF ATOPIC DERMATITIS AND OTHER SKIN CONDITIONSPharmaceuticalsACLARIS THERAPEUTICS, INC.
Apr 25, 20242024/0132505PYRROLOPYRIMIDINE ITK INHIBITORSPharmaceuticalsACLARIS THERAPEUTICS, INC. · patent 12,297,203 granted from it
Feb 29, 20242024/0067643SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAMEPharmaceuticalsACLARIS THERAPEUTICS, INC. · patent 12,281,111 granted from it
Feb 8, 20242024/0043398METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDSOrganic fine chemistryACLARIS THERAPEUTICS, INC. · patent 12,384,757 granted from it
Nov 16, 20232023/0365555CRYSTALLINE POLYMORPH FORM A OF A JAK INHIBITORAND METHODS FOR ITS PREPARATIONPharmaceuticalsACLARIS THERAPEUTICS, INC.
Sep 14, 20232023/0286950METHODS OF SYNTHESIZING DEUTERATED SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDSOrganic fine chemistryACLARIS THERAPEUTICS, INC.
Aug 3, 20232023/0242505PROCESS, COMPOSITIONS, AND CRYSTALLINE FORMS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDSPharmaceuticalsACLARIS THERAPEUTICS, INC.
Jun 29, 20232023/0202999METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDSOrganic fine chemistryACLARIS THERAPEUTICS, INC. · patent 11,767,309 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 5 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ACRS · research, not advice